Plenary Sessions

  • Thursday, June 29

    8:30 AM - 9:30 AM
    “The History of the Undersea and Hyperbaric Medical Society (1967-2017)”
    Speakers: Richard Moon, MD & Peter Bennett, PhD

    4:30 PM - 5:30 PM
    “HBO2 for Mild Traumatic Brain Injury”
    Speaker: Dr. Lin Weaver, MD

    Read more

  • Friday, June 30

    8:30 AM - 9:30 AM
    "An Update on the UHMS Clinical Practice Guidelines"

    Speakers: John Feldmeier, DO & Jaleh Mansouri, MD

    4:30 PM - 5:30 PM
    "Emergency and Critical Care Hyperbaric Medicine: A Lost Art"

    Speakers: Ian Grover, MD & Peter Witucki, MD

    Read more

  • Saturday, July 1

    8:30 am - 9:30 am
    "International Perspectives on Hyperbaric Oxygen Therapy"

    1:00 pm - 2:00 pm
     "New Pearls of Wisdom in the Diving and Hyperbaric Medicine Literature"

    4:30 pm - 5:30 pm
     "A Futurist’s Guide to Undersea and Hyperbaric Medicine: Where
    will we be in another 50 years"


    8:30 AM - 9:30 AM
    "International Perspectives on Hyperbaric Oxygen Therapy"

    Speakers: Gerardo Bosco, MD; Mahito Kawashima, MD & Folke Lind, MD

    dino Gerardo Bosco, MD Kawashima1 Mahito Kawashima, MD LIND WEBFolke Lind, MD 

    Innovative Therapeutic strategies in the treatment of femoral head necrosis- Bosco
    Innovative Therapeutic strategies in the treatment of refractory osteomyelitis- Kawashima
    Innovative Therapeutic strategies in the treatment neurosurgical infections- Lind

    Currently, the Undersea and Hyperbaric Medicine Society has approved Hyperbaric Oxygen Therapy (HBOT) for 14 different diseases. Indeed, HBOT has been demonstrated in several clinical studies to enhance the body’s innate ability to repair, to regenerate and to be a useful adjunct therapy for many chronic and acute conditions. To date HBOT indications are still under investigations requiring to clarify molecular and clinical mechanisms as per bone diseases (edema, necrosis and infections).

    University of Padua is widely committed in Hyperbaric Medicine both in training and research.

    In particular, the department of Biomedical Science has established a Second Level Master “Diving and Hyperbaric Medicine” addressed to graduates in Medicine and Surgery and a High Education Course in “Technical and Health management in Diving and Hyperbaric Chamber environment”. The main objective of the Master is to train a specific professional profile: from directly giving the appropriate medical care to patients up to the capability to lead the medical direction or the clinical activities management in a diving & hyperbaric medicine unit. The aim of the high education course is to improve technical, healthcare and managerial skills on the technicians and nurses. Both Master’s and High Education course’s program include frontal, seminars of expertise and laboratory “Hands on” real working scenarios of underwater and hyperbaric condition.

    Clinical and basic research on diving and hyperbaric medicine is performed in our Department, with a particular attention on the efficacy of HBOT in Osteonecrosis (ON), wound infections and healing. Our studies aim to point out possible molecular mechanisms involved in tissues regeneration (especially bone) promoted by HBOT. Recently we published a retrospective study where we evidenced the efficacy of Hyperbaric oxygen treatment in 217 ANFH patients (144 men and 73 women, mean age 53.8, stage FICAT I-II-III) for four consecutive years. Enrolled patients were treated with 90 HBO sessions (compressed oxygen for 82 minute at 2.5 ATA) over 12 months and conditions were evaluated by MRI and Visual Analogue Scale (VAS) pain score. Obtained data show that HBO significantly alleviated joint pain, improved joint structure in patients at all stages and such improvements remain substantially unchanged for about 4 years. Hip surgery was not necessary in most of the patients with stage I and II and in almost half the patients with stage III. In another recent work we tried to drive out possible molecular mechanisms underpinning the effectiveness of HBOT in ANFH. We monitored serum RANKL and OPG of 23 ANFH patients (FICAT I-II-III) treated with 2 sequential series of HBOT (60 total sessions) and interestingly we found that OPG concentration significantly increased already at the 15th session, suggesting an anti-osteoclastic activity of the therapy. This hypothesis was further supported by the finding that also pro-inflammatory cytokines plasmatic levels (IL1b, IL-6, TNFa) are modulated in response to HBOT and this modulation goes in a direction that inhibit osteoclast activation and differentiation. These findings contributed to the recently acceptance of AVFHN by European Committee for Hyperbaric Medicine as indication to treatment with HBO by the consensus conference of Lille (ECHM, May 2016).

    Our most recent challenge is trying to use hyperbaric oxygenation to improve in regenerative medicine. We aim to understand if and how HBO may a) accelerate the efficacy of adipose derived stem cells (ADSCs) differentiation into bone or endothelial cells precursor, b) enhance the probability of success of tissue engineered implants. 

    1:00 PM - 2:00 PM
    "New Pearls of Wisdom in the Diving and Hyperbaric Medicine Literature"
    Speakers: 2 UHM Fellows TBD

    4:30 PM - 5:30 PM
    "A Futurist’s Guide to Undersea and Hyperbaric Medicine: Where will we be in another 50 years"
    Speakers: Simon Mitchell, MD and Stephen Thom, MD


    Read more